The microtiter SDI test is more advantageous than the SDI test for assessing the chemosensitivity of human tumor cells.

S. Kohnoe, Y. Emi, Y. Sakaguchi, Yoshihiko Maehara, T. Kusumoto, K. Sugimachi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The in vitro succinate dehydrogenase inhibition (SDI) test was adapted to be used with microtiter plates and this microtiter SDI (mSDI) test was evaluated for clinical use of chemosensitivity testing, as compared to findings with the SDI test. The optimal conditions of the mSDI test were determined: (1) 2-5 x 10(4) cells/well; (2) enzymatic disaggregation of solid tumors with the use of a mixture of 0.2% pronase, 0.25% collagenase, 0.1% DNase for 20 min at 37 degrees C; (3) addition of 10 mM sodium succinate in the colorimetric reaction; and (4) use of dimethyl sulfoxide (DMSO) as a solvent for extraction of formazan product. Good correlations were observed between the mSDI and the SDI tests when S-180 cells (r = 0.890-0.996) or 16 human fresh tumor cells (r = 0.731-0.999) were exposed to six anti-cancer drugs (carboquone, adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil). Thus, the mSDI test facilitates testing of a large number of drugs with minimal amounts of specimens, and is expected to replace the SDI test for chemosensitivity testing of clinical tumor cells.

Original languageEnglish
Pages (from-to)145-152
Number of pages8
JournalAnti-cancer drugs
Volume2
Issue number2
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Succinate Dehydrogenase
Neoplasms
Carbazilquinone
Aclarubicin
Formazans
Pronase
Deoxyribonucleases
Succinic Acid
Mitomycin
Collagenases
Dimethyl Sulfoxide
Fluorouracil
Pharmaceutical Preparations
Doxorubicin
Cisplatin
Sodium

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

The microtiter SDI test is more advantageous than the SDI test for assessing the chemosensitivity of human tumor cells. / Kohnoe, S.; Emi, Y.; Sakaguchi, Y.; Maehara, Yoshihiko; Kusumoto, T.; Sugimachi, K.

In: Anti-cancer drugs, Vol. 2, No. 2, 01.01.1991, p. 145-152.

Research output: Contribution to journalArticle

Kohnoe, S. ; Emi, Y. ; Sakaguchi, Y. ; Maehara, Yoshihiko ; Kusumoto, T. ; Sugimachi, K. / The microtiter SDI test is more advantageous than the SDI test for assessing the chemosensitivity of human tumor cells. In: Anti-cancer drugs. 1991 ; Vol. 2, No. 2. pp. 145-152.
@article{c7a08569e807461ebd676fcca6232b7d,
title = "The microtiter SDI test is more advantageous than the SDI test for assessing the chemosensitivity of human tumor cells.",
abstract = "The in vitro succinate dehydrogenase inhibition (SDI) test was adapted to be used with microtiter plates and this microtiter SDI (mSDI) test was evaluated for clinical use of chemosensitivity testing, as compared to findings with the SDI test. The optimal conditions of the mSDI test were determined: (1) 2-5 x 10(4) cells/well; (2) enzymatic disaggregation of solid tumors with the use of a mixture of 0.2{\%} pronase, 0.25{\%} collagenase, 0.1{\%} DNase for 20 min at 37 degrees C; (3) addition of 10 mM sodium succinate in the colorimetric reaction; and (4) use of dimethyl sulfoxide (DMSO) as a solvent for extraction of formazan product. Good correlations were observed between the mSDI and the SDI tests when S-180 cells (r = 0.890-0.996) or 16 human fresh tumor cells (r = 0.731-0.999) were exposed to six anti-cancer drugs (carboquone, adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil). Thus, the mSDI test facilitates testing of a large number of drugs with minimal amounts of specimens, and is expected to replace the SDI test for chemosensitivity testing of clinical tumor cells.",
author = "S. Kohnoe and Y. Emi and Y. Sakaguchi and Yoshihiko Maehara and T. Kusumoto and K. Sugimachi",
year = "1991",
month = "1",
day = "1",
doi = "10.1097/00001813-199104000-00004",
language = "English",
volume = "2",
pages = "145--152",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The microtiter SDI test is more advantageous than the SDI test for assessing the chemosensitivity of human tumor cells.

AU - Kohnoe, S.

AU - Emi, Y.

AU - Sakaguchi, Y.

AU - Maehara, Yoshihiko

AU - Kusumoto, T.

AU - Sugimachi, K.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The in vitro succinate dehydrogenase inhibition (SDI) test was adapted to be used with microtiter plates and this microtiter SDI (mSDI) test was evaluated for clinical use of chemosensitivity testing, as compared to findings with the SDI test. The optimal conditions of the mSDI test were determined: (1) 2-5 x 10(4) cells/well; (2) enzymatic disaggregation of solid tumors with the use of a mixture of 0.2% pronase, 0.25% collagenase, 0.1% DNase for 20 min at 37 degrees C; (3) addition of 10 mM sodium succinate in the colorimetric reaction; and (4) use of dimethyl sulfoxide (DMSO) as a solvent for extraction of formazan product. Good correlations were observed between the mSDI and the SDI tests when S-180 cells (r = 0.890-0.996) or 16 human fresh tumor cells (r = 0.731-0.999) were exposed to six anti-cancer drugs (carboquone, adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil). Thus, the mSDI test facilitates testing of a large number of drugs with minimal amounts of specimens, and is expected to replace the SDI test for chemosensitivity testing of clinical tumor cells.

AB - The in vitro succinate dehydrogenase inhibition (SDI) test was adapted to be used with microtiter plates and this microtiter SDI (mSDI) test was evaluated for clinical use of chemosensitivity testing, as compared to findings with the SDI test. The optimal conditions of the mSDI test were determined: (1) 2-5 x 10(4) cells/well; (2) enzymatic disaggregation of solid tumors with the use of a mixture of 0.2% pronase, 0.25% collagenase, 0.1% DNase for 20 min at 37 degrees C; (3) addition of 10 mM sodium succinate in the colorimetric reaction; and (4) use of dimethyl sulfoxide (DMSO) as a solvent for extraction of formazan product. Good correlations were observed between the mSDI and the SDI tests when S-180 cells (r = 0.890-0.996) or 16 human fresh tumor cells (r = 0.731-0.999) were exposed to six anti-cancer drugs (carboquone, adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil). Thus, the mSDI test facilitates testing of a large number of drugs with minimal amounts of specimens, and is expected to replace the SDI test for chemosensitivity testing of clinical tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=0026135297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026135297&partnerID=8YFLogxK

U2 - 10.1097/00001813-199104000-00004

DO - 10.1097/00001813-199104000-00004

M3 - Article

C2 - 1958859

AN - SCOPUS:0026135297

VL - 2

SP - 145

EP - 152

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -